Well Phio Pharmaceuticals just gave short sellers the kind of day that makes them consider doing OnlyFans instead. In short, Phio went full diamond hands yesterday, surging 300% after the company dropped some seriously bullish Phase 1b trial results for its experimental cancer treatment, PH-762.

(Source: Giphy) 

Interesting, more details please…

See, Phio’s headline-grabbing cancer drug, PH-762, is designed to turn the immune system into a tumor-seeking missile—and as expected, the company reported that patients in it’s Phas 1b trial saw some game-changing results, including: Two patients with cutaneous squamous cell carcinoma achieved a complete response (a.k.a., 100% tumor clearance). 1 patient clocked a partial response with 90% tumor clearance and another patient maintained stable disease without progressions. But the bigly part about it all? Is that there was zero dose-limiting toxicities or major side effects of the trial. 

(Source: StockTwits) 

Meaning, Phio Pharmaceuticals may actually be onto something. Naturally, acting Chief Medical Officer Mary Spellman basically said as much, adding they’re excited to push into higher doses. Translation: Let’s see how far we can turn this up without breaking the dial. 

Now with that that said, if you’re rolling your eyes thinking, “Great, another pump-and-dump biotech story,” I’d think twice. Simply put, PH-762 isn’t just some random Hail Mary drug—it’s powered by Phio’s proprietary INTASYL RNAi tech, which blocks the proteins that suppress the immune system’s ability to attack cancer—telling them to sit down and shut up harder than Reddit telling advertisers theri platform isn’t just a cesspool of degeneracy.

(Source: Yahoo Finance) 

But, but, but… there’s more to the story here. You see, Phio’s trial is focused on treating advanced stages of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma using PH-762 as a neoadjuvant therapy (basically a pre-surgery assist). In plain English? They’re testing this drug on some of the toughest cancers out there, and the fact that it’s showing these kinds of results is a big deal.

What’s more is that, the trend in the biotech world right now is none other than immunotherapy. It’s one of the hottest areas in oncology, and Phio’s early data suggests they might have a novel approach that doesn’t just treat cancer but (potentially) obliterates it. For this reason, shares of Phio became more explosive than a Chipotle bathroom visit, with trading volume spiking to 220 times its daily average.

(Source: Giphy) 

By midday, Phio was the top gainer on U.S. markets, hitting its highest levels in eight months. For a stock that’s been limping along for the past year, Monday’s rally was like a shot of adrenaline straight to the heart. 

However, before you mortgage the house to load up on PHIO shares, keep in mind that early-stage trials are notoriously tricky. And while these results are promising, there’s still a long way to go before PH-762 hits the market. Regulatory hurdles, larger trials, and, oh yeah, the need for money to fund all of this could throw a wrench into Phio’s plans. Meaning, sure, Phio’s up 300% now, but one bad trial result could send it back to penny-stock purgatory faster than you can refresh your Robinhood app.

(Source: Giphy) 

At the end of the day though, Phio Pharmaceuticals just gave retail investors the kind of day they live for, with a monster rally fueled by legit science (for once). The company’s INTASYL tech and PH-762 drug candidate have the potential to disrupt the cancer treatment landscape, but it’s still early days.

In the meantime, Phio gets its moment in the sun—and retail traders get a story to tell. Whether this stock continues its ascent or flames out remains to be seen. But still, keep this stock on your radar going forward. Of course, do what you will with this information and place your bets accordingly. As always, stay safe and stay frosty, friends! Until next time…

P.S. If you want to have full access to our Insider Trader Tool and see where executives and congress members are piling their millions, all you have to do is become a Stocks.News Premium member (it’s less than the cost of a HBO Max subscription). Go here and start piggybacking the insider’s trades, there’s a reason these folks are crushing the best hedge funds to ever exist by triple digits.

Stocks.News does not hold positions in companies mentioned in the article.